 Connection
Christian Young to Mice
This is a "connection" page, showing publications Christian Young has written about Mice.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.400 |
|
|
|
-
Nguyen KA, DePledge LN, Bian L, Ke Y, Samedi V, Berning AA, Owens P, Wang XJ, Young CD. Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice. J Immunother Cancer. 2023 09; 11(9).
Score: 0.072
-
Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, S?nchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res. 2013 Jul 01; 73(13):4075-85.
Score: 0.035
-
Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ, Ilkun O, Pereira R, Abel ED, Anderson SM. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 2011; 6(8):e23205.
Score: 0.031
-
Young CD, Nolte EC, Lewis A, Serkova NJ, Anderson SM. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res. 2008; 10(4):R70.
Score: 0.025
-
Li X, Ke Y, Hernandez AL, Yu J, Bian L, Hall SC, Nolan K, Wang JH, Young CD, Wang XJ. Inducible nitric oxide synthase (iNOS)-activated Cxcr2 signaling in myeloid cells promotes TGF?-dependent squamous cell carcinoma lung metastasis. Cancer Lett. 2023 08 28; 570:216330.
Score: 0.018
-
Ke Y, Li BZ, Nguyen K, Wang D, Wang S, Young CD, Wang XJ. IL-22RA2 Is a SMAD7 Target Mediating the Alleviation of Dermatitis and Psoriatic Phenotypes in Mice. J Invest Dermatol. 2023 11; 143(11):2243-2254.e10.
Score: 0.018
-
Boss MK, Ke Y, Bian L, Harrison LG, Lee BI, Prebble A, Martin T, Trageser E, Hall S, Wang DD, Wang S, Chow L, Holwerda B, Raben D, Regan D, Karam SD, Dow S, Young CD, Wang XJ. Therapeutic Intervention Using a Smad7-Based Tat Protein to Treat Radiation-Induced Oral Mucositis. Int J Radiat Oncol Biol Phys. 2022 03 01; 112(3):759-770.
Score: 0.016
-
Strait AA, Woolaver RA, Hall SC, Young CD, Karam SD, Jimeno A, Lan Y, Raben D, Wang JH, Wang XJ. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGF?/PD-L1 blockade-treated squamous cell carcinoma. Commun Biol. 2021 08 25; 4(1):1005.
Score: 0.016
-
Hernandez AL, Young CD, Bian L, Weigel K, Nolan K, Frederick B, Han G, He G, Devon Trahan G, Rudolph MC, Jones KL, Oweida AJ, Karam SD, Raben D, Wang XJ. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clin Cancer Res. 2020 06 15; 26(12):3058-3070.
Score: 0.014
-
Wu FL, Nolan K, Strait AA, Bian L, Nguyen KA, Wang JH, Jimeno A, Zhou HM, Young CD, Wang XJ. Macrophages Promote Growth of Squamous Cancer Independent of T cells. J Dent Res. 2019 07; 98(8):896-903.
Score: 0.013
-
Li F, Bian L, Iriyama S, Jian Z, Fan B, Luo J, Wang DD, Young CD, Han G, Wang XJ. Smad7 Ameliorates TGF-?-Mediated Skin Inflammation and Associated Wound Healing Defects but Not Susceptibility to Experimental Skin Carcinogenesis. J Invest Dermatol. 2019 04; 139(4):940-950.
Score: 0.013
-
Luo J, Bian L, Blevins MA, Wang D, Liang C, Du D, Wu F, Holwerda B, Zhao R, Raben D, Zhou H, Young CD, Wang XJ. Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. Clin Cancer Res. 2019 01 15; 25(2):808-818.
Score: 0.013
-
Luo JJ, Young CD, Zhou HM, Wang XJ. Mouse Models for Studying Oral Cancer: Impact in the Era of Cancer Immunotherapy. J Dent Res. 2018 06; 97(6):683-690.
Score: 0.012
-
Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. J Natl Cancer Inst. 2017 11 01; 109(11).
Score: 0.012
-
Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL. Association of FGFR1 with ERa Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clin Cancer Res. 2017 Oct 15; 23(20):6138-6150.
Score: 0.012
-
Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res. 2017 Jun 30; 19(1):74.
Score: 0.012
-
Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Cancer Res. 2016 08 15; 76(16):4752-64.
Score: 0.011
-
Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis. PLoS Genet. 2015 Jul; 11(7):e1005291.
Score: 0.010
-
Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, S?nchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J Clin Invest. 2013 Oct; 123(10):4329-43.
Score: 0.009
-
Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, S?nchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013 Aug 27; 110(35):14372-7.
Score: 0.009
-
Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, S?nchez V, Koland J, Muller WJ, Arteaga CL, Cook RS. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 2012 May 15; 72(10):2672-82.
Score: 0.008
-
Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, S?nchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A. 2012 Jan 03; 109(1):221-6.
Score: 0.008
-
Cook RS, Garrett JT, S?nchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res. 2011 Jun 01; 71(11):3941-51.
Score: 0.008
-
Lambert JR, Eddy VJ, Young CD, Persons KS, Sarkar S, Kelly JA, Genova E, Lucia MS, Faller DV, Ray R. A vitamin D receptor-alkylating derivative of 1a,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila). 2010 Dec; 3(12):1596-607.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|